At-Risk Populations
Protease Inhibitor-Treated Patients More Likely To Engage in Risky Sex
Published in Medical Letter on the CDC and FDA, November 30th, 1998
Researchers at Emory University's Rollins School of Public Health, Atlanta, Georgia, the University of Alabama at Birmingham School of Public Health, and the U.S. Centers for Disease Control and Prevention (CDC) studied sexually active persons living with HIV and found that those treated with protease inhibitors were more likely to report inconsistent condom use compared to persons not treated with protease inhibitors.
Ralph DiClemente,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Public Health
Home HIV Tests Reaching High-Risk Individuals - T. cruzi
Blood Donor Management Strategies May Need Revision - Conference Coverage (AASLD)
Small Dose of HEV Results in Subclinical Infection - Dengue Fever (Vaccine Development)
Thai Scientists Moving Forward in Battle Against Dengue - Heart Disease (Epidemiology)
Gap Between Races Growing in Heart Disease Deaths - Opportunistic Infections
"Entamoeba histolytica Infections Among HIV Infected Patients in the United States: Clinical Presentation, Diagnostic Methods, and Treatment Choices." - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
